MBX Biosciences (MBX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.29
- Estimate
- -$0.84
- Surprise
- -52.7%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
MBX Biosciences (MBX) reported a wider loss than forecast — adjusted EPS of -$1.29 against the -$0.84 estimate (a 52.7% shortfall).
Coverage in the report window
- MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights — fiscal.ai, 2026-11-09
- MBX Biosciences Q3 EPS $(1.29) Misses $(0.84) Estimate — benzinga, 2026-11-09
Where TrendMatrix's rating stands now
TrendMatrix currently rates MBX Sell at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -52.7% surprise compares with a -14.0% four-quarter average.
What argues against it
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $56.65
- Price target
- $83.26
- Stop
- $52.68
- Upside to target
- +47.0%
- Reward-to-risk
- 3.1:1
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
MBX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.60B
- P/E (fwd)
- -13.6
- 52-week range
- $23.07–$72.64
- Off 52-week high
- 22.0%
- RSI (14)
- 55
- Volume vs avg
- 0.56×
- Score today
- 5.6/10